Use Nektar Therapeutics management performance together with your assets to protect against small markets fluctuations as well as to check it against diversification policy that fits your risk preferences.
Nektar Management Effectiveness
The company has return on total asset (ROA) of (11.29) % which means that it has lost $11.29 on every $1 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (62.67) % meaning that it created substantial loss on money invested by shareholders.
Nektar Profit Margins
The company has Profit Margin (PM) of (177.96) % which may suggest that it does not properly executes on its current pricing strategies or is unable to controls all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (161.69) % which suggests for every dolor of sales it generated a net operating loss of -1.62.
Nektar Therapeutics is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 41,122. Nektar claims roughly 423 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Mr. Howard W. Robin is President, Chief Executive Officer, Director of Nektar Therapeutics. He has served as President and Chief Executive Officer since January 2007 and has served as a member of board of directors since...
Mr. Robert B. Chess is an Independent Chairman of board of Directors of Nektar Therapeutics. He is the Chairman of board of directors and has served as a director since May 1992. He is currently the chairman of the board...
Nektar employes about 423 people. The company is managed by 16 executives with total tenure of roughly 76 years, averanging almost 4.0 years of service per executive having 26.0 employee per reported executive.
Return on Nektar Manpower
Revenue Per Employee
184.7 K
Revenue Per Executive
4.9 M
Net Loss Per Employee
328.7 K
Net Loss Per Executive
8.7 M
Working Capital Per Employee
354.4 K
Working Capital Per Executive
9.4 M
Nektar Earnings Per Share
According to company disclosure Nektar Therapeutics has Earnings Per Share of -1.22 times. This is 215.09% lower than that of Healthcare sector, and 377.27% lower than that of Biotechnology industry, The Earnings Per Share for all stocks is 182.43% higher than the company.
Earnings per Share is one of the most important measures of current share price of a firm, and is used by investors to determine company overall profitability especially when it is compared to EPS of similar companies.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
